Introduction
Before we can consider how drugs affect benign enlargement of the prostate we must ask two questions: on what do the drugs act, and what do we expect them to do ?
Benign enlargement of the prostate begins from the inner group of prostatic glands. With increasing age all the elements of the inner prostatic glands become hyperplastic. In the established condition the mass of nodules surrounds the urethra and the outer prostate, or the prostate proper, is stretched around the hyperplastic inner glands (Franks 1954) . The line of separation between the two gland groups is usually quite well defined and in the ordinary operations of subtotal prostatectomy this is the plane of cleavage, leaving the outer prostate behind as the so-called surgical capsule. The histology of the nodules shows a wide range of structure. Epithelium of ducts or acini, or muscular or fibrous stroma in any combination, take part in the process. The hyperplastic collagenous stroma is always the loose, pale-staining stroma propria, i.e. the subepithelial, periductal and periurethral stroma. Hyperplasia is characteristically nodular. The nodules, although apparently well defined, almost always merge with the surrounding gland tissue at some point on their circumference. The surgically removed prostate generally consists of a mass of such nodules (Moore 1943 , Franks 1969 . Morphologically, there are five main types of nodule: fibrovascular, fibromuscular, the pure muscular nodule or 'leiomyoma', the fibroadenomatous and the fibromyoadenomatous types in which all elements are involved. The epithelium in the nodules shows a wide range of variation. It may be flat and atrophic, it may be tall columnar and apparently actively secreting, it may be transitional or squamous or it may be a multilayered cuboidal epithelium. Occasionally the hyperplasia may involve myoepithelial cells. Intracystic, fibrous and epithelial papillk are sometimes seen, particularly in dilated ducts near the urethra, and occasionally there may be a peculiar intra-acinar proliferation of spindle cells. Atrophic changes are common in some nodules and similar to those seen in the outer prostatic glands. Cystic change is particularly frequent, the cysts and atrophic acini being lined by a flattened, low, cuboidal epithelium. The stroma of the nodules is made up of interlacing strands of smooth muscle and collagen arranged in much the same way as in the normal prostate. This then is the tissue on which we expect our drugs to act.
We must now ask what we expect them to do. Presumably we expect them to relieve symptoms and the predominant symptom concerned is urinary obstruction. It must be remembered that urinary obstruction is not as a rule due only to the presence of benign nodular hyperplasia. All the examples already described were from autopsy specimens removed from patients without clinical evidence of urological disease. Although benign nodular hyperplasia alone may cause urinary obstruction either by physically obstructing the urethra or by interference with the muscle or nerves supplying the sphincter, this is relatively uncommon. If tissue removed at operation from the prostate is examined, some superadded condition, often vascular, is almost invariably found. Infarcts are common, and there may be acute or chronic inflammation or not infrequently quite large and unsuspected areas of carcinoma. Thus the symptoms of benign nodular hyperplasia may be produced by a wide variety of lesions, some of which may be transitory. This makes it extremely difficult to assess the results of treatment in the short term; any improvement may not be a direct consequence of the treatment used. This may help Table 1 Results of various treatments for benign enlargement of the prostate Authors reporting
Treatment
Good results Bad results Castration White (1895) Kelsey (1896) Lilienthal (1895) Robinson (1896) Athanasow (1898) Deming ct al. (1935a, b) and others Testosterone Van Cappellen (1933) and many others (see Vidgoff 1939) Inhibin Lower et al. (1935) Champy (1937) CEstrogen Wugmeister (1937) Moore & McClellan (1938) No treatment Clarke (1937) to explain some of the apparently contradictory results listed in Table 1 , which shows that good and bad results have been described following almost every type of endocrine treatment. Perhaps the most significant of these is in the series reported by Clarke (1937) , who found that his best results were achieved by not giving any treatment at all. Finally, in view of the wide range of structures present in the enlarged gland, it seems unlikely that any one drug can produce a sufficient degree of atrophy of all the different types of epithelium, connective tissue and muscle to provide a permanent cure.
Mr J E Castro' (Royal Postgraduate Medical School, London W12) Trial Designs
At present patients with benign prostatic hypertrophy who need treatment undergo prostatectomy. Mortality from this depends upon the patient's age, associated medical conditions and the presence of acute retention. Most surgeons report an overall mortality of 3% (Wells 1953) 'Present address: National Institute for Medical Research, Mill Hill, London NW7 IAA but this increases to 13 3% in patients over the age of 80 (Watts 1968). Lesser but annoying complications are common (Jeejeebhoy 1961 , Holtgrewe & Valk 1964 and refinements of surgical technique cannot be expected to reduce them. Alternative treatments for this essentially benign condition are therefore needed and it is in this context that medical methods have been tried.
Based upon the somewhat shaky premise that benign prostatic hypertrophy is a result of changes in the hormonal milieu, androgens (Day 1939 , Kahle & Maltry 1940 ), cestrogens (Roberts 1966 , Cook 1963 and progestogens (Geller et al. 1967 , Wolf & Madsen 1968 ) have been tried, but the results were confusing due to the methods by which the drugs were assessed.
Selection ofPatients
Our observations relate to a double-blind, controlled trial of spironolactone (Aldactone 50 mg b.d.). Patients given spironolactone had an overall improvement compared to placebo after three months of treatment, but this advantage was lost after six months (Castro et al. 1971) .
Patients with symptoms of bladder neck obstruction and benign enlargement of the prostate on digital rectal examination were studied. The following groups of patients were excluded from the trial: (1) Those with evidence of prostatic cancer, clinical, radiological, or from serum acid phosphatase testing. (2) Those who had had urethral or bladder surgery.
(3) Those with other radiological abnormalities of the lower urinary tract. (4) Those taking drugs which affect the urinary tract. (5) Those with a blood urea above 80 mg/100 ml. (6) Those with acute retention.
Investigations
Patients were investigated by many measurements because the important indices of response were not clear. In each patient a symptom score was derived and frequency and nocturia were recorded by the patient for one week so that mean values could be deduced. The transverse diameter of the prostate was estimated by digital rectal examination and blood urea was measured. Excretion urograms and retrograde cystograms were taken and various measurements were made from these radiographs (Castro et al. 1969) , particularly the postmicturition residual urine by planimetry (Griffiths & Castro 1970) . The micturating cystogram was combined with simultaneous measurements of urinary dynamics and direct measurement of residual urine by catheterization.
Randomization
After the initial investigations patients were randomly and secretly allocated to either active or
